Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults

Inclusion Criteria: * Adult men or women aged 18 to 49 years inclusive. * Able and willing to provide written informed consent to participate. * Healthy, as determined by medical history, physical examination, and vital signs. * Willing to receive the unlicensed (VAX102) vaccine given as an i.m. or s.c. injection. * Willing to provide multiple blood specimens collected by venipuncture. * Females should avoid becoming pregnant during the course of the study * Women of childbearing potential must have a negative urine pregnancy test within 24 hours preceding receipt of the first and preceding receipt of the second (booster) vaccination. * Must exhibit comprehension of the study requirements; expressed availability for the required study period and expect to reside in the study area during the entire study period, and ability to attend scheduled visits. Exclusion Criteria: * Persons under 18 years old or 50 years or older. * Persons with chronic illnesses such as cancer, diabetes, liver or kidney disease. * Person currently pregnant, nursing mothers or planning a pregnancy within one month of vaccination. * Persons who have had a prior serious reaction to influenza vaccine. * Persons with a history of anaphylactic-type reaction to injected vaccines. * Persons with a history of drug or chemical abuse in the year preceding the study. * Persons who received an influenza vaccine for the current influenza season or those who plan to receive an influenza vaccine while participating in the study. * Persons who received any other vaccine within one week prior to enrollment (may delay enrollment). * Persons who have had a respiratory illness or illness with fever within three days of study enrollment (may delay enrollment). * Persons currently participating in another research study involving any study medications (medicines or vaccines).